Ribo has advanced RBD1119, a siRNA therapeutic targeting coronary artery disease, into Phase 2 clinical trials in Europe. The drug addresses residual thrombotic risk in stable coronary artery disease patients who remain at risk despite standard antiplatelet and anticoagulant therapy, with a design intended to reduce bleeding complications associated with current antithrombotic agents.
Key Points
- siRNA therapeutic targets thrombotic risk in coronary artery disease
- Designed to provide antithrombotic effect with reduced bleeding risk
- Phase 2 trial submission represents advancement in anticoagulation strategy
Longevity Analysis
Coronary artery disease remains a leading driver of mortality despite decades of antiplatelet and anticoagulant therapy, primarily because current interventions carry significant hemorrhage risk that limits dosing and duration of protection. A therapeutic that can modulate clotting tendency through gene silencing, rather than enzyme inhibition, could shift the risk-benefit calculus in cardiovascular management. For individuals with established atherosclerotic disease, sustained antithrombotic protection without proportional bleeding hazard would meaningfully extend both healthspan and lifespan by reducing recurrent events and allowing longer, safer treatment windows.
Original published by LT Wire.